From a therapeutic point of view, the germline variants found in genes involved in DNA damage response and double-strand repair mechanisms indicate the tumours could have been sensitive to the treatment with PARP1/2 inhibitors such as olaparib and niraparib through mechanisms of synthetic lethality [45]. The gene discussed is PARP1; the disease is neoplasm.